Welcome to our dedicated page for INmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on INmune Bio stock.
INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
INmune Bio (NASDAQ: INMB) reported 2025 results and a business update on March 30, 2026. Key items: CORDStrom MAA filing to the UK MHRA mid-summer 2026 with subsequent EMA and expected U.S. BLA in Q4 2026, completed three pilot commercial manufacturing runs, and FDA alignment for an adaptive Phase 2b/3 pathway for XPro in early Alzheimer’s.
Financials: net loss $45.9M, R&D $20.7M, impairment $16.5M, cash $24.8M and runway through Q1 2027; sold 4.30M shares for $27.5M net.
INmune Bio (NASDAQ: INMB) will report year-ended December 31, 2025 financial results and provide a corporate update on Monday, March 30, 2026 at 4:30 PM Eastern Time. Management will host a conference call and live audio webcast; replay available through April 13, 2026.
Dial-in numbers, conference ID, webcast link, and replay details were provided for investor access.
INmune Bio (NASDAQ: INMB) announced that its Phase 2 MINDFuL trial of XPro1595 (pegipanermin) was highlighted in a plenary at AD/PD 2026 as an example of matching inflammatory biomarker enrichment to mechanism of action.
The company reports that MINDFuL showed consistent efficacy signals in an inflamed patient subgroup and that INmune Bio has FDA alignment to advance an integrated Phase 2b/3 registrational program for biomarker‑enriched early Alzheimer’s patients.
INmune Bio (NASDAQ: INMB) will host a webinar on February 27, 2026 at 9:30 a.m. ET to discuss the registrational pathway for XPro1595 in early Alzheimer’s disease with inflammation biomarkers.
Speakers will review Phase 2 MINDFuL results, FDA End‑of‑Phase 2 feedback supporting a biomarker‑enriched registrational study design, and the Company's Phase 3 roadmap including plans to pursue global partnerships. Registration link is provided for investors and clinicians.
INmune Bio (NASDAQ: INMB) will host a webinar on February 26, 2026 at 1:00 p.m. ET to present new clinical data for CORDStrom™ in recessive dystrophic epidermolysis bullosa (RDEB).
Presentations will highlight MissionEB Phase III results including EBDASI skin score improvements versus placebo, pediatric weight gain, reductions in pain and itch, and enhanced daily functioning as reported by principal investigators.
INmune Bio (NASDAQ: INMB) received FDA minutes confirming alignment on an integrated Phase 2b/3 registration pathway for XPro1595 in early Alzheimer’s disease. The FDA raised no objection to a single master protocol, ~300-participant Phase 2b (9-month assessment), ~1,000-participant full program with an 18-month Phase 3, CDR-SB as sole primary endpoint, and a ~20% non-enriched exploratory cohort.
The FDA supported an inflammation-based biomarker enrichment strategy and allowed final powering and statistical plans to be specified in the protocol to be submitted for review.
INmune Bio (NASDAQ: INMB) submitted a pre-submission package for CORDStrom to the UK MHRA on February 10, 2026, seeking early scientific and regulatory feedback to streamline a full MAA.
The company reported MissionEB trial improvements in itch, pain, skin integrity and QoL, three commercial pilot manufacturing runs meeting release criteria in Stevenage, and plans to file an MAA mid-summer 2026 with EU and U.S. submissions targeted for Q4 2026. CORDStrom holds U.S. Orphan Drug and Rare Pediatric Disease designations; recent legislation reauthorizes the FDA Rare Pediatric Disease PRV program through 9/30/2029.
INmune Bio (NASDAQ: INMB) CEO David Moss reviewed 2025 progress and outlined 2026 priorities, highlighting clinical and regulatory milestones for two lead programs: CORDStrom for recessive dystrophic epidermolysis bullosa (RDEB) and XPro (XPro1595) for Alzheimer’s disease. Key 2025 items include three commercial pilot-scale manufacturing runs for CORDStrom, a planned MAA submission in mid‑summer 2026 to the UK MHRA and a targeted BLA submission late 2026 to FDA (timelines subject to regulatory feedback). XPro’s Phase 2 MINDFuL showed biomarker‑defined signals (EMACC effect size 0.27) guiding a precision‑medicine registrational path. Cash and equivalents were approximately $27.7M as of Sept 30, 2025, with financing and rebates expected to fund operations through year‑end 2026.
INmune Bio (NASDAQ: INMB) announced a peer-reviewed overview on mesenchymal stromal cell (MSC) therapies published in Cytotherapy, titled “Fate and Function of Exogenously Administered MSCs: Current Insights and Future Directions.”
Lead scientist on INmune’s CORDStrom™ R&D, Dr Nikita M. Patel, was one of the senior authors on an invitation-only working party that reviewed current knowledge and gaps for MSC development. Topics included systemic delivery, local/depot delivery (the CORDStrom™ approach), and in vivo persistence. The company said it is initially developing CORDStrom™ for RDEB and expects to file a BLA and MAA in 2026.
INmune Bio (NASDAQ: INMB) reported new Phase 2 neuroimaging analyses from the MINDFuL trial of XPro1595 in early Alzheimer’s disease patients with elevated neuroinflammation (ADi). Presented at CTAD Dec 1-4, 2025, the PerpPD+ grey-matter MRI analysis showed a trend toward slowed progression of cortical disarray in XPro1595-treated, dose-compliant ADi participants at 24 weeks.
The company says these imaging signals align with directional improvements in biological, cognitive, and neuropsychiatric endpoints and that additional MRI analyses are expected in 2026.